AI-generated analysis. Always verify with the original filing.
ALX Oncology Holdings Inc. reported Q4 and full year 2025 financial results, including GAAP net loss of ($22.8) million or ($0.42) per share for Q4 and ($101.7) million or ($1.90) per share for the year, with cash of $48.3 million as of December 31, 2025 extended to 1H 2028 post $140.4 million net proceeds from a $150 million equity offering. The company provided updates on evorpacept and ALX2004 clinical programs, validating CD47 as a biomarker and outlining upcoming milestones.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report on Form 8-K, including Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated February 27, 2026 104 Cover Page Interactive Data File (for
| Metric | Value | Basis |
|---|---|---|
| GAAP Net Loss | $-22.80 | GAAP |
| Diluted EPS | $-0.42 | GAAP |
| GAAP Net Loss | $-101.70 | GAAP |
| Diluted EPS | $-1.90 | GAAP |
Barbara Klencke, M.D.
Effective: 2026-02
served in interim capacity since September 2025
Material Agreement